FIELD: medicine; biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to amylin receptor agonists, and can be used in medicine. Invention is an analogue of pramlintide, selectively modified by substituents, fatty carboxylic acids, at different positions of the amino acid sequence.
EFFECT: such pramlintide analogues can act as an effective antidiabetic agent and serve to treat patients with metabolic disorders and the ability to utilise glucose.
14 cl, 4 dwg, 15 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| LONG-ACTING AGONISTS OF RECEPTORS Y2 AND(OR) Y4 | 2009 |
|
RU2504550C2 |
| DUAL GLP1/GIP OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | 2013 |
|
RU2652783C2 |
| NOVEL GLUCAGON ANALOGUES | 2012 |
|
RU2610175C2 |
| ACYLATED GLP-1 COMPOUNDS | 2006 |
|
RU2434019C2 |
| NOVEL GLUCAGON ANALOGUES | 2011 |
|
RU2559320C2 |
| SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID SALT AND LUBRICANT | 2019 |
|
RU2807183C2 |
| ANALOGUES OF EGF(A) WITH SUBSTITUENTS-FATTY ACIDS | 2017 |
|
RU2747877C2 |
| STABLE PROTRACTED GLP-1/GLUCAGON RECEPTOR CO-ANTAGONISTS FOR MEDICAL USE | 2014 |
|
RU2683039C2 |
| ACYLATED INSULIN ANALOGUES STABILISED WITH RESPECT TO PROTEASES | 2009 |
|
RU2571857C2 |
| FGF21 DERIVATIVES WITH ALBUMIN BINDING AGENT A-B-C-D-E- AND THEIR APPLICATION | 2010 |
|
RU2525393C2 |
